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TheCD56 differentiation antigen, recognized by anti-Leu-19 and NKH-1 mAbs,
is a 200-220-kD glycoprotein that is expressed predominantly on human NK cells
and a minor subset ofT lymphocytes mediating MHC-unrestricted cytotoxicity (1-4).
A growing body ofevidence has demonstrated that surface differentiation antigens
expressed on functionally distinct lymphocyte subpopulations are implicated in their
specific functions, however, the functional role ofCD56 in NK cytotoxicity has not
yet been determined.
Recently, it has been revealed that CD56 is an isoform of the neural cell adhesion
molecule (N-CAM) (5), which is expressed on neural and muscle tissues and in-
volved in homotypic adhesive interactions (6). This finding suggests that CD56 on
NK cells may also be involved in cell adhesion, analogous to the function of N-CAM
on neural cells. In the present report, we show that CD56 on human NK cells does
function as an adhesion molecule in NK-target cell interaction.
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mAbs.
￿
Unlabeled anti-Leu-19 mAb (4) was purchased from Becton Dickinson & Co. (Moun-
tain View, CA). Unlabeled and phycoerythrin (PE)-conjugated NKH-1 mAbs (1) were pur-
chased from Coulter Immunology (Hialeah, FL). Unlabeled anti-LFA-1 mAb (25.3) (7) was
purchased from Cosmo Bio (Tokyo, Japan). Ascites containing anti-ICAM-1 mAb (RRl/1)
(8) and those containing anti-LFA-3 mAb (TS2/9) (9) were kindly provided by Dr. T. A.
Springer(Harvard Medical School, Boston, MA) and Dr. S. J. Burakoff(Dana-Farber Cancer
Institute, Boston, MA), respectively.
Cells.
￿
The glioblastoma (U251MG, A172), neuroblastoma (GOTO), melanoma (G361),
and leukemia (Molt-4, K562) cell lines were obtained from the Japanese Cancer Research
Resources Bank (Tokyo, Japan). PBMC were isolated from the blood ofhealthy donors using
Ficoll-Hypaque. After depleting monocytes and B cells by plastic adherence and passage
through nylon wool, nonadherent lymphocytes were fractionated on discontinuous Percoll
gradients as described (10). The low-buoyant density lymphocytes isolated from the interface
between 30 and 35% consisted of80-85% NKH-1* cellsas estimated by flow cytometry and
were served as the NK cells. NK cells were cultured for IS h with 100 U/ml of rIL-2, as de-
scribed (10), and then subjected to the cytotoxicity and conjugate formation assays.
Immunofluorescence andFlow Cytometry.
￿
Immunofluorescenee and flow cytometric analysis
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were performed as described (10). In indirect immunofluorescence, FITC-conjugated goat
anti-mouse Ig (FGAM) antibody (Olympus, Tokyo,Japan) was used as the second antibody.
Cytotoxicity Assay.
￿
Cytotoxicity was measured using a standard 4 h 5'Cr release assay as
described (10).
Conjugate Formation Assay.
￿
Untreated or mAb-treated NK cells(106) and target cells (2 x
105) were mixed in a final volume of 100 1 .1 and centrifuged at 500 g for 1 min. After a 20-min
incubation at room temperature, the cells were gently resuspended and counted under mi-
croscopy. NK cells and target cells were clearly discriminated by their distinctive difference
in cell size. Target cells binding at least two NK cells were scored as positive and 200 target
cells were counted in triplicate.
Results and Discussion
Recently, two antigen-independent pathways of effector-target cell binding have
been demonstrated that are mediated by the interaction between CD2 on effector
cells and LFA-3(CD58) on target cells, and by that between LFA-1 (CDlla/CD18)
on effector cells and ICAM-1 (CD54) on target cells (11). Relative contribution of
either pathway to cell binding is variable among combinations ofeffector and target
cells (11). These two adhesion pathways are involved also in NK cell interaction with
target cells (12). To assess the putative adhesive function of CD56 on NK cells in
a correlation with these known two pathways, we first examined the expression of
CD56 among various target cells in parallel with those of LFA-3 and ICAM-1. Sev-
eral tumor cell lines of neuroectodermal origin (U251MG and A172 glioblastomas,
GOTO neuroblastoma, and G361 melanoma) were revealed to express CD56 as es-
timated by flow cytometry with NKH-1 mAb, although Molt-4 and K562 leukemia
cell lines were CD56- (data not shown). This preferential expression of CD56 on
neural tumor cell lines is consistent with the recent finding that CD56 is identical
to N-CAM (5). Among them, we used a glioblastoma cell line U251MG (NKH-
1', ICAM-1 - , LFA-3+) (Fig. 1) and a T acute lymphoblastic leukemia (TALL) cell
line Molt-4 (NKH-1 - , ICAM-1 +, LFA-3') (Fig. 1) in the following studies, since
they were highly susceptible for activated NK cells prepared by culturing low-buoyant
density PBL with rIL-2 for 18 h.
We then examined the inhibitory effect of an anti-CD56 mAb (anti-Leu-19) on
NK cell-mediated cytotoxicity against these two targets in conjunction with an anti-
LFA-3 mAb (TS2/9) and/or an anti-LFA-1 mAb (25.3). Anti-LFA-3 mAb was preferred
rather than anti-CD2 mAb to abrogate the CD2/LFA-3 interaction since anti-CD2
mAb may activate NK cell cytotoxicity in some circumstances (12). Anti-LFA-1 mAb
was also preferred rather than anti-ICAM-1 mAb since ICAM-1 is not the sole ligand
for LFA-1 (13). As shown in Fig. 2, NK cell-mediated cytolysis against the CD56'
target U251MG was only partially inhibited by anti-LFA-1 or anti-LFA-3 mAb alone
and also by the combination of both anti-LFA-1 and anti-LFA-3 mAbs. In contrast,
the cytotoxicity against the CD56- target Molt-4 was also partially blocked by anti-
LFA-1 or anti-LFA-3 mAb alone, however, was completely abrogated by the combi-
nation ofboth anti-LFA-1 and anti-LFA-3 mAbs. Anti-Leu-19 mAb, when used alone,
did not inhibit the NK cytotoxicity against U251MG and Molt-4. However, when
used in combinations with anti-LFA-1 and/or anti-LFA-3 mAbs, anti-Leu-19 mAb
did exhibit synergistic inhibitory effects, and a complete inhibition was attained only
after the treatment with all the three mAbs, when CD56' U251MG was used as
the target (Fig. 2). No such synergistic inhibitory effect of anti-Leu-19 mAb wasNKH-1
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observed when the CD56- Molt-4 was used as the target (Fig. 2). A similar syner-
gistic inhibitory effect with anti-LFA-1 and/or anti-LFA-3 mAbs was also observed
when another anti-CD56 mAb, NKH-1, was used and when CD56+ GOTO, but
not CD56- K562, were used as the targets (datanot shown). These results indicate
that CD56 on NK cells is involved in NK cell-mediated cytotoxicity when the target
cells express CD56.
We next examined the effect of anti-Leu-19 mAb on NK cell binding to CD56'
or CD56 - target cells in conjunction with anti-LFA-1 and/or anti-LFA-3 mAbs. As
shown in Fig. 3, synergistic inhibitory effects of anti-Leu-19 mAb with anti-LFA-1
and/or anti-LFA-3 mAbs, similar to those observed in NK cell-mediated cytotox-
icity (Fig. 2), were observed again on NK cell binding to target cells only when
FIGURE 2.
￿
Inhibitory effect ofanti-Leu-19, anti-LFA-
1, and/or anti-LFA-3 mAbs on NK cell-mediated cyto-
toxicity. Low-buoyant density PBL highly enriched for
NK cells were cultured with 100 U/ml of rIL-2. After
an 18-h culture, effector NK cells were preincubated with
orwithoutanti-Leu-19 mAb(10pg/ml) and/or anti-LFA-
1 mAb(25.3; 10 hg/ml) for30 min at 37°C, and then
cytotoxicity wastested against U251MG or Molt-4 target
cells, whichwere preincubated with or without anti-LFA-
3 mAb (TS2/9; 1:100 dilution ofascites) for30 minat
37°C, at an E/T ratio of 5:1 .1760
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￿
Inhibitory effect ofanti-Leu-19, anti-LFA-
1, and/or anti-LFA-3 mAbs on conjugateformationbe-
tween NK cellsandtarget cells. NK cells andU251MG
or Molt-4 target cells preincubated with anti-Leu-19,
anti-LFA-1, and/or anti-LFA-3 mAbs, as describedin Fig.
2, were mixed at an E/T ratioof 5:1, and centrifuged.
Aftera20-min incubation at room temperature, thecells
were gently resuspended andcounted. Results are indi-
cated as mean percent target cellsbindingat least two
NK cells after counting 200 target cells in triplicate.
CD56+ U251MG was used as the target. A similar inhibitory effect of anti-Leu-19
mAb on NK cell binding to target cells was also observed when either the effector
NKcellsorthe target U251MG cellswaspretreated with anti-Leu-19 mAb, washed,
and then mixed together (data not shown), demonstrating that anti-Leu-19 mAb
blocks NK cell binding at both the effector and the target sites. These results indi-
cate that CD56 on NK cells does contribute to NK cell binding when the target
cells express CD56, and suggest that the binding is homotypic, i.e., CD56 on NK
cells binds to CD56 on target cells. This is consistent with the homotypic binding
of N-CAM demonstrated in neural and muscle tissues.
From these results, it is evident that CD56 on NK cells is involved in NK-target
cell interactions. The contribution ofCD56to NK cell cytotoxicityandbindingcould
be demonstrated onlywhen the target cells express CD56. This explains the failure
to demonstrate an inhibitory effect of anti-Leu-19 and NKH-1 mAbs on NK cyto-
toxicity in the previous studies (1-4), in which only CD56- cells, such as K562 and
Molt-4, were used as the targets. In addition, the inhibitory effects of anti-Leu-19
mAb could be demonstrated only in the presence of anti-LFA-1 and/or anti-LFA-3
mAbs. This indicates that the homotypic interaction between CD56 (N-CAM) on
NK and target cells constitutes the third pathway ofNK-target cell binding, other
than the two adhesion pathways mediated by the LFA-1/ICAM-1 and CD2/LFA-3
interactions, although the NK cell binding to CD56- target cells is predominantly
mediated by the latter two pathways.
It is evident from our data that CD56 on NK cells can function as an adhesion
molecule, however, the physiological significance of the rather confined expression
ofN-CAMto NK cells and a minor subset ofTlymphocytesmediatingMHC-unre-
stricted cytotoxicity in peripheral blood remains to be determined. Since N-CAM
is expressed in various tissues (6), the adhesive function of CD56 on the particular
lymphocytes may bedirectly involved intheirinteractionwith these tissuesand cells
expressing N-CAM. Further studies will be needed to test this possibility.
Summary
TheCD56 differentiation antigen, recognized by anti-Leu-19 and NKH-1 mAbs,
is a 200-220-kD glycoprotein that is expressed predominantly on human NK cells
and a minor subset ofT lymphocytes mediating MHC-unrestricted cytotoxicity.
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(N-CAM) prompted us to examine the adhesive function ofCD56 in the NK-target
cell interaction. Synergistic inhibitory effects of anti-CD56 mAbs with anti-LFA-1
and/or anti-LFA-3 mAbs were demonstrated on NK cell-mediated cytotoxicity and
on NK cell binding to target cells only when the target cells also express CD56.
These findings indicate that CD56 on NK cells can serve as the third pathway of
cell adhesion other than those mediated by the CD2/LFA-3 and LFA-1/ICAM-1 in-
teractions, and is involved in NK cell cytotoxicity when interacting with the cells
bearing N-CAM.
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